Reposted by @stonerqueer64.bsky.social
Taking a GLP-1 drug benefits patients with type 2 diabetes and chronic kidney disease, regardless of CVD status, by preventing kidney events and reducing mortality. More on the FLOW trial analysis here: www.tctmd.com/news/semaglu...
tctmd.com
Semaglutide Benefits Diabetic Patients Regardless of CVD Status: FLOW Subanalysis
The results support the potential to change the trajectory of kidney function decline and extend life expectancy.